This is an open-label study to evaluate the safety and preliminary efficacy of Codivir in 12
mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion.
Treatment will begin in the hospital, participants will be discharged at Day 4 and continue
the treatment up to Day 10 at home and followed up to day 28.